Diaceutics

Diaceutics’ mission is simple: to help every patient get the right test and treatment at the right time.  The company is in a good position to benefit from the growing use of precision medicine to treat diseases such as cancer and MS.

Its main platform, DXRX, is the world’s largest repository of real-world testing data and it brings great insights into the successful commercialisation of precision medicine diagnostics. The software platform is now fully invested and benefits from multi-year subscription revenues, excellent gross margins and a relatively fixed cost base, all operating in a high growth industry.

In 2024, the company launched PMx, a new service that allows it to work more closely with drug makers when new medicines are introduced, creating opportunities for faster growth. Most of Diaceutics’ income comes from repeat customers. It is debt-free, well-funded and on track to deliver reliable profit growth. 

Diaceutics provides data analytics and diagnostic support to pharmaceutical companies, relying heavily on the collection and processing of sensitive healthcare data.

A breach or misuse of this data could lead to reputational damage, legal liability, and financial consequences, as well as loss of client and patient trust. Cybersecurity is an important concern. 

Talent acquisition and retention is another risk. Diaceutics depends on highly skilled professionals in data science, healthcare analytics, and regulatory affairs - areas where competition for talent is intense. Failure to recruit and retain these skilled people could negatively affect productivity and strategic execution.